biostudies-literatureUnknown12Wang F<h4>Introduction</h4>Drug-resistant respiratory pathogens in COPD patients pose a major therapeutic challenge. Colistin is a last-resort treatment for drug-resistant infections. But emerging resistance and hepatorenal toxicity limit its use, which highlights the need for combination strategies to improve its efficacy and safety. This study investigated the antibacterial effect of the combination of benzbromarone and colistin against drug-resistant pathogens associated with COPD.<h4>Methods and results</h4>In this study, MIC determination experiments revealed that respiratory pathogens from COPD patients exhibited high resistance rates to several conventional antibiotics. Furthermore, the checkerboard assay showed that benzbromarone alone had no antibacterial effect but markedly lowered theFrontiers in medicine1665514https://www.ebi.ac.uk/biostudies/studies/S-EPMC12457112biostudies-literatureAntimicrobial effect of benzbromarone combined with colistin against multidrug-resistant bacteria.PMC12457112Li HBao XWang FfalseAntimicrobial effect of benzbromarone combined with colistin against multidrug-resistant bacteria.<h4>Introduction</h4>Drug-resistant respiratory pathogens in COPD patients pose a major therapeutic challenge. Colistin is a last-resort treatment for drug-resistant infections. But emerging resistance and hepatorenal toxicity limit its use, which highlights the need for combination strategies to improve its efficacy and safety. This study investigated the antibacterial effect of the combination of benzbromarone and colistin against drug-resistant pathogens associated with COPD.<h4>Methods and results</h4>In this study, MIC determination experiments revealed that respiratory pathogens from COPD patients exhibited high resistance rates to several conventional antibiotics. Furthermore, the checkerboard assay showed that benzbromarone alone had no antibacterial effect but markedly lowered the2025-01-01T00:00:00Z20252026-05-01T03:22:26.414Z2026-05-01T03:11:07.812ZS-EPMC124571124100139210.3389/fmed.2025.1665514